×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NASDAQ:SEEL

Seelos Therapeutics (SEEL) Stock Forecast, Price & News

$0.62
+0.02 (+3.36%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.58
$0.64
50-Day Range
$0.51
$0.93
52-Week Range
$0.48
$3.59
Volume
1.03 million shs
Average Volume
1.62 million shs
Market Capitalization
$65.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.62
30 days | 90 days | 365 days | Advanced Chart
Receive SEEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Seelos Therapeutics logo

About Seelos Therapeutics

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Headlines

Seelos: Q1 Earnings Snapshot
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SEEL
Employees
15
Year Founded
N/A

Sales & Book Value

Annual Sales
$380 thousand
Book Value
$0.43 per share

Profitability

Net Income
$-66.05 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
100,680,000
Market Cap
$65.36 million
Optionable
Not Optionable

Company Calendar

Today
5/28/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

630th out of 1,424 stocks

Pharmaceutical Preparations Industry

292nd out of 681 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

Is Seelos Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Seelos Therapeutics stock.
View analyst ratings for Seelos Therapeutics
or view top-rated stocks.

When is Seelos Therapeutics' next earnings date?

Seelos Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Seelos Therapeutics
.

What price target have analysts set for SEEL?

4 brokerages have issued 1-year target prices for Seelos Therapeutics' stock. Their forecasts range from $4.00 to $10.00. On average, they anticipate Seelos Therapeutics' share price to reach $7.50 in the next year. This suggests a possible upside of 1,117.3% from the stock's current price.
View analysts' price targets for Seelos Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Seelos Therapeutics' key executives?
Seelos Therapeutics' management team includes the following people:
  • Dr. Raj Mehra J.D., Ph.D., Founder, Chairman, CEO & Pres (Age 62, Pay $921.12k)
  • Mr. Michael J. Golembiewski, Chief Financial Officer (Age 50, Pay $416.93k)
  • Ms. Kimberly Farrand, Sr. Director of Clinical Devel. & Operations
  • Mr. Anthony Marciano, Chief Communications Officer
  • Gopal Krishna Ph.D., Head of Manufacturing & Technical Operations
  • Tim Whitaker M.D., Chief Medical Officer
What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK).

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

Who are Seelos Therapeutics' major shareholders?

Seelos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.96%), Vanguard Group Inc. (5.35%), Woodline Partners LP (2.65%), Mirae Asset Global Investments Co. Ltd. (1.83%), State Street Corp (1.65%) and Renaissance Technologies LLC (1.63%).
View institutional ownership trends for Seelos Therapeutics
.

Which institutional investors are selling Seelos Therapeutics stock?

SEEL stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, Connacht Asset Management LP, BlackRock Inc., DAVENPORT & Co LLC, JPMorgan Chase & Co., Northern Trust Corp, Goldman Sachs Group Inc., and Group One Trading L.P..
View insider buying and selling activity for Seelos Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Seelos Therapeutics stock?

SEEL stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Mirae Asset Global Investments Co. Ltd., Vanguard Group Inc., AdvisorShares Investments LLC, State Street Corp, Penserra Capital Management LLC, First Republic Investment Management Inc., and Citigroup Inc..
View insider buying and selling activity for Seelos Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Seelos Therapeutics?

Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $0.62.

How much money does Seelos Therapeutics make?

Seelos Therapeutics has a market capitalization of $65.36 million and generates $380 thousand in revenue each year.

How many employees does Seelos Therapeutics have?

Seelos Therapeutics employs 15 workers across the globe.

What is Seelos Therapeutics' official website?

The official website for Seelos Therapeutics is www.seelostherapeutics.com.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at (646) 293-2100, via email at [email protected], or via fax at 858-436-8155.

This page was last updated on 5/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.